Association of recurrent abortion, fetal loss and severe pre-eclampsia with hereditary thrombophilias and antiphospholipid antibodies in pregnant women of central Brazil;Associação entre abortamentos recorrentes, perdas fetais, pré-eclâmpsia grave e trombofilias hereditárias e anticorpos antifosfolípides em mulheres do Brasil Central

Revista Brasileira de Ginecologia e Obstetricia

Volumn 29, Issue 11, 2007, Pages 561-567

  Figueiró Filho, Ernesto Antonio ^a,b   De Oliveira, Vanessa Marcon ^b  

^a Universidade Federal de Mato Grosso do sul UFMS ^*  (United States)

^b FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

Author keywords

Abortion, habitual; Antibodies, antiphospholipid; Pregnancy complications, hematologic; Pregnancy, high risk; Pr eclampsia; Thrombophilia genetics

Indexed keywords

EID: 41149123196     PISSN: 01007203     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0100-72032007001100003     Document Type: Article

References (45)

1. Pereira AC, Jesús NR, Lage LV, Levy RA. Imunidade na gestação normal e na paciente com lúpus eritematoso sistémico (LES). Rev Bras Reumatol. 2005;45(3):134-40.
2. Krabbendam I, Franx A, Bots ML, Fijnheer R, Bruinse HW. Thrombophilias and recurrent pregnancy loss: a critical appraisal of the literature. Eur J Obstet Gynecol Reprod Biol. 2005;118(2):143-53.
3. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol. 2003; 101 (6): 1333-44.
4. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet. 1999;353(9161)1348-53.
5. Pierangeli SS, Gharavi AE, Harris EN. Experimental thrombosis and antiphospholipid antibodies: new insights. J Autoimmun. 2000;15(2):241-7.
6. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314(7076):253-7.
7. Rai R. Obstetric management of antiphospholipid syndrome. J Autoimmun. 2000;15(2):203-7.
8. Schust DJ, Hill JA. Abortamento recorrente. In: Berek JS, editor. Tratado de ginecologia. 13a ed. Rio de Janeiro: Guanabara Koogan; 2005. p. 996-1023.
9. Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost. 2002;87(5):791-5.
10. De Santis M, Cavaliere AF, Straface G, Di Gianantonio E, Caruso A. Inherited and acquired thrombophilia: pregnancy outcome and treatment. Reprod Toxicol. 2006;22(2):227-33.
11. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, et al. Thrombophilia in pregnancy: a systematic review. BrJ Haematol. 2006;132(2):171-96.
12. Haemostasis and Thrombosis Task Force British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. BrJ Haematol. 2001;114(3):512-28.
13. Medeiros SF. Abortamento habitual. In: Federação Brasileira das Associações de Ginecologia e Obstetrícia. Tratado de ginecologia. Rio de Janeiro: Revinter; 2001. p. 565-76.
14. Balasch J. Antiphospholipid antibodies: a major advance in the management of recurrent abortion. Autoimmun Rev. 2004;3(3):228-33.
15. Mattar R, Camano L, Daher S. Aborto espontâneo de repetição e atopia. Rev Bras Ginecol Obstet. 2003;25(5):331-5.
16. Kupfermine MJ, Fait G, Many A, Gordon D, Eldor A, Lessing JB. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol. 2000;96(1):45-9.
17. Harris EN. Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol. 1990;94(4):476-84.
18. Triplett DA, Stocker KF, Unger GA, Barna LK. The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost. 1993;70(6):925-31.
19. The British Committee for Standards in Haematology. Guidelines on the investigation and management of thrombophilia. J Clin Pathol. 1990;43(9):703-9.
20. Ubbink JB, Hayward Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr. 1991;565(1-2):441-6.
21. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families. Blood. 1994;84(4):1031-5.
22. Grandone E, Margaglione M, Colaizzo D, d'Addedda M, Cappuci G, Vecchione G, et al. Factor V Leiden is associated with repeated and recurrent fetal losses. Thromb Haemost. 1997;77(5):822-4.
23. Schieve LA, Tatham L, Peterson HB, Toner J, Jeng G. Spontaneous abortion among pregnancies conceived using assisted reproductive technology in the United States. Obstet Gynecol. 2003;101 (5 Pt 1):959-67.
24. Barini R, Couto E, Mota MMM, Santos CTM, Leiber SR, Batista SC. Fatores associados ao aborto espontâneo recorrente. Rev Bras Ginecol Obstet. 2000;22(4):217-23.
25. Couto E, Barini R, Zacearía R, Annicchino-Bizzacchi JM, Passini Junior R, Pereira BG, et al. Association of anticardíolipin antibody and C677T in methylenetetrahydrofolate reductase mutation in woman with recurrent spontaneous abortions: a new path to thrombophilia? São Paulo Med J. 2005;123(1):15-20.
26. Vora S, Shetty S, Salvi V, Satoskar P, Ghosh K. A comprehensive screening analysis of antiphospholipid antibodies in Indian women with fetal loss. Eur J Obstet Gynecol Reprod Biol. 2007 Jul 16. [Epub ahead of print]
27. Costa OLN, Brandão C, Silva MMR, Pimentel KS, Santiago MB. Anticorpos antifosfolípides em mulheres com antecedentes de perdas gestacionais: estudo caso-controle. Rev Bras Reumatol. 2005;45(3):119-23.
28. Lockshin MD. Antiphospholipid antibody syndrome. Rheum Dis Clin North Am. 1994;20(1):45-59.
29. Dreyfus M, Hedelin G, Kurtnahorsky R, Lehmann M, Viville B, Langer B, et al. Antiphospholipid antibodies and preeclampsia: a case-control study. Obstet Gynecol. 2001;97(1):29-34.
30. Yamamoto T, Yoshimura S, Geshi Y, Sasamori Y, Okinaga S, Kobayashi T, et al. Measurement of antiphospholipid antibody by Elisa using purified beta 2-glycoprotein I in preeclampsia. Clin Exp Immunol. 1993;94(1):196-200.
31. Lee RM, Emlen W, Scott JR, Branch DW, Silver RM. Anti-beta 2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome. Am J Obstet Gynecol. 1999;181 (3):642-8.
32. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, et al. Increased fetal loss in women with heritable thrombophilia. Obstet Gynecol Surv. 1997;52(3):155-6.
33. Hellgren M, Svensson PJ, Dahlbäch B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995;173(1):210-3.
34. De Stefano V, Simione P, Rossi E, Tormene D, Za T, Pagnan A, et al. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica. 2006;91(5):695-8.
35. McColl MD, Ramsay JE, Tait RC, Walker ID, McCall F, Conkie JA, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997;78(4):1183-8.
36. Meglic L, Stegnar M, Milanez T, Bozic M, Peterlin B, Peternel P, et al. Factor V Leiden, prothrombin 2021 OG a methylenetetrahydrofolate reductase 677C T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancyrelated venous thromboembolism. Eur J Obstet Gynecol Reprod Biol. 2003;111(2):157-63.
37. Powers RW, Minich LA, Lykins DL, Ness RB, Crombleholme WR, Roberts JM. Methylenetetrahydrofolate reductase polymorphism, folate, and susceptibility to preeclampsia. J Soc Gynecol Investig. 1999;6(2):74-9.
38. Nelen WL, Blom HJ, Steegers EA, den Heijer M, Thomas CM, Eskes TK. Homocysteine and folate levels as risk factors for recurrent early pregnancy loss. Obstet Gynecol. 2000;95(4):519-524.
39. van den Berg M, Boers GH. Homocystinuria: what about mild hyperhomocysteinaemia? Postgrad Med J. 1996;72(851):513-8.
40. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ. 1998;316(7135):894-8.
41. Murphy RP, Donoghue C, Nallen RJ, D'Mello M, Regan C, Whitehead AS, et al. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol. 2000;20(1):266-70.
42. Younis JS, Ohel G, Brenner B, Haddad S, Lanir N, Ben-Ami M. The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. BJOG. 2000;107(3):415-9.
43. Dizon-Townson DS, Kinney S, Branch DW, Ward K. The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol. 1997;34(3):217-23.
44. Dulicek P, Chrobák L, Kalousek I, Pesavová L, Pecka M, Stránský P. Is factor V Leiden a risk factor for fetal loss? Acta Medica (Hradec Kralove). 1999;42(3):93-6.
45. Soligo AGS, Barini R, Carvalho ECC, Annichino-Bizzacchi J. Prevalência dos fatores trombofílícos em mulheres com infertilidade. Rev Bras Ginecol Obstet. 2007;29(5):23540.